
What smart money is saying about Carl Zeiss Meditec
1 fund in our archive has pitched Carl Zeiss Meditec — most recently Harding Loevner Global Small Companies Equity in September 2025.
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers products and solutions for the diagnosis and treatment of eye diseases; and systems and consumables for cataract, retinal, and refractive surgeries. It serves practicing ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The Microsurgery segment offers visualization solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, dental and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
Get an email when a fund writes about it
Fund coverage · 1 thesis
- Harding Loevner Global Small Companies EquitySeptember 2025
Carl Zeiss Meditec is positioned to benefit from long-term growth in the vision-care market despite short-term demand softness, with 51% of its sales from recurring revenue and a strong competitive advantage.
Read the full thesis
Read every full thesis on Carl Zeiss Meditec
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→